A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

We report the discovery and characterization of SM-406 (compound 2), a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). This compound binds to XIAP, cIAP1, and cIAP2 proteins with K(i) of 66.4, 1.9, and 5.1 nM, respectively. Compound 2 effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Compound 2 is currently in phase I clinical trials for the treatment of human cancer.

[1]  Yigong Shi,et al.  Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. , 2004, Trends in biochemical sciences.

[2]  Dajun Yang,et al.  Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. , 2008, Journal of medicinal chemistry.

[3]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[4]  Young Chul Park,et al.  Structural Basis of Caspase Inhibition by XIAP Differential Roles of the Linker versus the BIR Domain , 2001, Cell.

[5]  Shaomeng Wang,et al.  Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. , 2008, Journal of medicinal chemistry.

[6]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[7]  Shaomeng Wang.  Design of small-molecule Smac mimetics as IAP antagonists. , 2010, Current topics in microbiology and immunology.

[8]  Emad S. Alnemri,et al.  A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis , 2001, Nature.

[9]  Raimund Mannhold,et al.  IAP antagonists: promising candidates for cancer therapy. , 2010, Drug discovery today.

[10]  Xiaodong Wang,et al.  Structural and biochemical basis of apoptotic activation by Smac/DIABLO , 2000, Nature.

[11]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[12]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[13]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[14]  Bruce A.J. Ponder,et al.  Cancer genetics , 2001, Nature.

[15]  R. Liddington,et al.  Structural Basis for the Inhibition of Caspase-3 by XIAP , 2001, Cell.

[16]  M. Bertrand,et al.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. , 2008, Molecular cell.

[17]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[18]  John Calvin Reed,et al.  Distinct BIR Domains of cIAP1 Mediate Binding to and Ubiquitination of Tumor Necrosis Factor Receptor-associated Factor 2 and Second Mitochondrial Activator of Caspases* , 2006, Journal of Biological Chemistry.

[19]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[20]  Sheng Jiang,et al.  Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. , 2007, Journal of the American Chemical Society.

[21]  B. Ponder.  Cancer genetics , 2001, Nature.

[22]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[23]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[24]  Shaomeng Wang,et al.  SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. , 2008, Cancer research.

[25]  Shaomeng Wang,et al.  Structure-based design of potent, conformationally constrained Smac mimetics. , 2004, Journal of the American Chemical Society.

[26]  Xueliang Fang,et al.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. , 2004, Analytical biochemistry.

[27]  L. Languino,et al.  IAP regulation of metastasis. , 2010, Cancer cell.

[28]  Chao-Yie Yang,et al.  Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. , 2009, Journal of the American Chemical Society.

[29]  S. Srinivasula,et al.  Mechanism of XIAP-mediated inhibition of caspase-9. , 2003, Molecular cell.

[30]  Xiaodong Wang,et al.  TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.

[31]  R. Korneluk,et al.  The inhibitors of apoptosis (IAPs) as cancer targets , 2007, Apoptosis.

[32]  Chunying Du,et al.  Smac/DIABLO Selectively Reduces the Levels of c-IAP1 and c-IAP2 but Not That of XIAP and Livin in HeLa Cells* , 2004, Journal of Biological Chemistry.

[33]  D. Nicholson,et al.  From bench to clinic with apoptosis-based therapeutic agents , 2000, Nature.

[34]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[35]  Shaomeng Wang,et al.  Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. , 2009, Journal of medicinal chemistry.

[36]  Su Qiu,et al.  Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). , 2008, Journal of medicinal chemistry.

[37]  Su Qiu,et al.  Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. , 2010, Journal of medicinal chemistry.

[38]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[39]  Shaomeng Wang,et al.  Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. , 2006, Journal of medicinal chemistry.

[40]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[41]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[42]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[43]  R. Rich,et al.  Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac* , 2003, Journal of Biological Chemistry.

[44]  Shaomeng Wang,et al.  Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. , 2004, Journal of medicinal chemistry.

[45]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[46]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[47]  R. Korneluk,et al.  XIAP: Apoptotic brake and promising therapeutic target , 2001, Apoptosis.

[48]  S. Srinivasula,et al.  IAPs: what's in a name? , 2008, Molecular cell.

[49]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[50]  Shaomeng Wang,et al.  Design of Small‐Molecule Peptidic and Nonpeptidic Smac Mimetics , 2009 .

[51]  Emad S. Alnemri,et al.  correction: A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis , 2001, Nature.

[52]  W. Fairbrother,et al.  The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer , 2007, Clinical Cancer Research.